Redwood AI

AI platform for chemical synthesis, drug discovery, and defense applications

DISCLAIMER

Forward-Looking Information

This presentation may contain "forward-looking information" within the meaning of applicable Canadian securities legislation ("forward-looking statements") with respect to Redwood AI Corp. (the "Company"). All information, other than statements of historical facts, included in this presentation that addresses activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company's business, operations, plans and other such matters, is forward-looking information. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that the Company's assumptions may not be correct and that actual results may differ materially from those projected in such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as "anticipate", "believe", "will", "may", "could", "plan", "potential" and similar expressions.

Forward-looking statements contained in this presentation and other forward-looking statements are based on management of the Company's opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Forward-looking statements contained in this presentation, but are not limited to statements with respect to: the Company's business strategy; future operations, growth, conditions and expected future developments; the timing and completion of corporate transactions; the satisfaction of conditions to closing of offerings, including the receipt, in a timely manner, of regulatory and other required approvals; the terms of the offering; the distribution; the intentions, plans and future actions of the Company; the business and future activities of the Company, including expected developments in the Company's business and operations; the expected benefits of transactions; future trends and operations; the Company's business strategy and objectives; management personnel, advisors and consultants; expectations regarding trends in the healthcare industry; the economy generally; the expectations of global pharmaceuticals and chemical manufacturing; contract development and manufacturing organization ("CDMO") market opportunity; the testing and sales of pharmaceuticals; the use of contract development and manufacturing organizations by biopharma; the growth of the CDMO market; the ability of the Company's AI model, processes and application; the transformative technology ability of the Company's AI model; the growth trajectory; and current and continued market position.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Readers are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements based on certain risk factors, which include, but are not limited to: the ability to complete transactions; the ability to achieve the desired synergies or benefits of transactions; the ability to market its products; the market price for the Company's securities; the volatility and subject to wide fluctuations in response to numerous factors, many of which are beyond the Company's control; liquidity; regulatory approvals; the Company's financial position and results of operations may differ materially from expectations; the Company expects to incur future losses and may never generate revenues; the Company may be unable to generate revenues or establish a subscription-based revenue model; the Company may require additional capital to support its business; the Company may be unable to maintain and keep employees; the Company's market opportunity and success is subject to significant uncertainty; the Company's intellectual property; cybersecurity and data security breaches; risks associated with operating in a complex healthcare and technology regulatory and legal environment subject to a wide variety of laws and regulations, including those relating to healthcare, consumer products, product liability and consumer protection; regulatory requirements; the ability to maintain effective internal controls; tax laws or interpretation thereof; data protection and privacy laws and regulations; risks associated with research, development or commercialization of products; unfavorable global economic and political conditions could adversely affect the Company's business, financial condition or results of operations; the Company may not be able to identify or complete acquisitions; and other risks discussed in documents filed by the Company with Canadian securities regulatory authorities, which are available under the Company's profile on SEDAR+.

The Company and its directors, officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable law. Accordingly, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Unless otherwise specified, all dollar amounts referenced herein are expressed in United States dollars.

Market & Industry Data

This presentation also contains references to certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third-party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

No securities regulatory authority has expressed an opinion about the securities and it is an offence to claim otherwise. An investment in the securities of the Company is speculative and involves a high degree of risk. There are certain risk factors associated with an investment in the Company's securities and these risk factors should be reviewed carefully and evaluated by readers. Investments in technology, including AI technology, issuers involve a significant degree of risk. An investment in these securities should only be made by persons who can afford the total loss of their investment.

WHAT IS REDWOOD AI?

Redwood AI is an AI-powered chemistry platform that helps discover new medicines, design chemical processes, and analyze chemical data across drug discovery, advanced materials, and defense applications.

The platform supports applications across scientific and strategic sectors including:

- Drug discovery and development
- Chemical synthesis and manufacturing
- Defense and chemical intelligence
- Advanced materials research

WHAT CAN REDWOOD AI'S PLATFORM DO?

- **Predict how complex chemicals can be produced**

- **Design and optimize new molecules**

- **Analyze large chemical datasets**

- **Identify efficient and scalable chemical manufacturing processes**

INDUSTRIES SERVED BY THE PLATFORM

Drug Discovery

- Redwood AI's platform can accelerate discovery of new medicines, design new molecules, and support future AI-driven drug candidate generation.

Chemical Manufacturing

- Redwood AI's platform can design more efficient and scalable chemical synthesis processes, helping reduce production costs.

Defense and National Security

- Redwood AI's platform can analyze chemical data to identify potential threats and support development of new materials used in defense systems.

- It can also identify and characterize unknown chemical compounds to support threat detection and safety monitoring.

Advanced Materials

- Redwood AI's platform can help identify new materials and optimize chemical properties for industrial and strategic applications.

WHY THESE INDUSTRIES NEED AI PLATFORMS

Chemical Complexity Is Increasing

⚇ Modern drugs, materials, and chemical products are becoming more complex to design and manufacture.[1]

Chemical Data Is Growing Rapidly

⚇ Large volumes of experimental and synthesis data require advanced tools to analyze and extract insights.[2]

Faster Development Is Critical

⚇ Companies and governments need faster ways to discover medicines, develop materials, and improve manufacturing efficiency.[3]

⚇ Drug development and chemical innovation remain slow and resource intensive, creating strong demand for technologies that can accelerate research and development.

Source 1: https://pmc.ncbi.nlm.nih.gov/articles/PMC10544322/
Source 2: https://pmc.ncbi.nlm.nih.gov/articles/PMC12333164/
Source 3: https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1201419/full

STRATEGIC APPLICATION AREAS

Drug Discovery & Therapeutics

- AI-driven analysis of chemical datasets to accelerate drug discovery and support future candidate generation.
  - **Example:** Identify promising drug candidates earlier in the discovery process.

Chemical Manufacturing & Process Optimization

- AI tools for optimizing synthesis pathways and improving scalability in pharmaceutical and chemical manufacturing.
  - **Example:** Identify lower-cost synthesis routes that improve manufacturing scalability.

Government & Public Safety

- Chemical data analysis to support hazardous material detection, border security, and safety monitoring.
  - **Example:** Faster classification of unknown chemical compounds during safety or forensic investigations.

Advanced Materials Development

- Discovery and design of new materials with potential applications across aerospace, energy, and defense.
  - **Example:** AI tools can help identify materials with specific performance characteristics for industrial or strategic applications.

Defense & Strategic Applications

- Chemical capabilities supporting threat detection, safety analysis, and materials research in intelligence defense environments.
  - **Example:** The platform could help identify risk profiles for unknown chemical compounds or seized materials, reducing the time and cost of laboratory testing.

MARKET OPPORTUNITY

Global Pharmaceutical Market Size
2020 to 2030 (USD Trillion)

Size, by Molecule Type, 2020 - 2030 (USD Trillion)

$1.6T

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030

■ Conventional Drugs (Small Molecules)   ■ Biologics & Biosimilars (Large Molecules)

Source: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report

Redwood's AI-powered chemistry platform operates across pharmaceutical development, AI-driven discovery, and emerging chemical intelligence applications.

- **Embedded within the $1.65T USD (2024) global pharmaceutical market, projected to exceed ~$2.35T USD by 2030.[1]**

- **Operates within the $197.4B+ USD global CDMO market, projected to grow ~$368.7B USD by 2034.[2]**

- **Exposure to the $6.9B USD (2025) AI-enabled drug discovery market, projected to reach ~$17.81B USD by 2034.[3]**

- **Exposure to the ~$2.7T USD (2024) global defense spending market, projected to exceed ~$6.3T by 2035 as AI and advanced analytics become increasingly embedded in national security systems.[4]**

Source 1: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
Source 2: https://www.precedenceresearch.com/pharmaceutical-cdmo-market
Source 3: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market
Source 4: https://www.sphericalinsights.com/press-release/defence-spending-market

AI ACCELERATION IN THE GLOBAL CDMO MARKET

Pharmaceutical CDMO Market Size
2025 to 2034 (USD Billion)

AI adoption in drug manufacturing and development is accelerating, creating a structural opportunity within the global CDMO market.

Market Growth

- The global CDMO market is projected to grow from $197.4B USD in 2025 to ~$368.7B USD by 2034.[1]

Why This Matters

- CDMOs underpin drug development and commercialization infrastructure.[2]

- Increasing molecule complexity and biologics demand require more advanced synthesis planning and scalable manufacturing solutions.[2]

- Redwood's AI-powered chemistry platform can improve synthesis planning, reduce costs, and increase manufacturing scalability within CDMO infrastructure.

# AI IN DRUG DISCOVERY AND MOLECULAR DESIGN

AI In Drug Discovery Market Size, by Application 2025 to 2035 (USD Billion)

Source: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market

AI adoption is accelerating in early discovery, molecular design, and candidate prioritization.

Market Growth

- The global AI in drug discovery market is projected to grow from $6.9B USD in 2025 to ~ $17.81B USD by 2035.[1]
- Forecasts consistently show double-digit growth as AI becomes embedded in early-stage discovery and design.[1]

Why This Matters

- Early-stage discovery and molecular design require significant time, cost, and repeated testing.
- AI enables broader exploration of chemical space and faster prioritization.
- Platforms that combine synthesis intelligence with discovery and candidate prioritization can improve efficiency across the drug development lifecycle.

Potential Strategic Upside

- AI-enabled discovery platforms also have the potential to generate proprietary drug candidates, enabling participation in drug sales and access to the significantly larger global pharmaceutical market.

AI AND CHEMICAL INTELLIGENCE IN DEFENSE APPLICATIONS

Global Defence Spending Market
2024 to 2035 (USD Trillion)

6.38 Tn

2.7 Tn

2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035

Source: https://www.sphericalinsights.com/press-release/defence-spending-market

AI adoption across defense and national security systems is accelerating, increasing demand for advanced analytics and chemical intelligence capabilities.

Market Growth

- The global defense spending market is projected to grow from ~$2.7T in 2024 to ~$6.38T by 2035.[1]
- Governments worldwide are increasing investment in AI, advanced analytics, and next-generation defense technologies.[1]

Why This Matters

- Defense organizations increasingly rely on AI-enabled systems to analyze complex datasets and support strategic decision-making.
- Chemical and materials intelligence plays an important role in national security, safety monitoring, and defense research programs.
- AI chemistry platforms can analyze chemical data to identify threats and support development of new materials used in defense systems.

REDWOOD AI OVERVIEW

Building an AI-powered chemistry platform that predicts chemical synthesis pathways, optimizes manufacturing processes, and analyzes chemical datasets to support drug discovery, industrial chemistry, and defense-related applications.

Our Technology

⚙ Redwood AI is building a proprietary AI-powered chemistry platform that uses advanced chemical analysis and machine learning to model, predict, and optimize synthesis pathways across drug discovery, chemical manufacturing, and strategic sectors including defense.

⚙ As the platform scales, each deployment expands Redwood's proprietary synthesis and reaction dataset. This growing data foundation improves model performance and supports future AI-enabled drug candidate generation and drug development pipeline support.

Core Platform

⚙ Redwood's core platform uses AI to analyze chemical data, design and optimize synthesis pathways, and help organizations develop new molecules more efficiently across pharmaceuticals, biotechnology, industrial chemistry, and strategic sectors including defense.

Commercialization Strategy

⚙ Redwood aims to commercialize its platform through a subscription-based software-as-a-service model, initially focused on pharmaceutical and biotechnology organizations.

Redwood AI intends to expand toward AI-enabled candidate generation and broader chemical intelligence capabilities, leveraging its growing proprietary data foundation.

REDWOOD AI TECHNOLOGY PLATFORM

Synthesis Intelligence

Models trained on billions of reactions predict efficient synthesis routes.

Process Optimization

Optimization algorithms identify reaction conditions that improve yield, purity, and efficiency.

Chemical Safety & Hazard Analysis

Analyzes chemical data to detect hazardous compounds, safety risks, and transport risks.

Advanced Compute Integration

Supports advanced computing techniques including quantum-inspired optimization

Conventional

Target molecule for analysis

AI-Assisted

Manual Process

Target molecule must be manually reviewed, with potentially thousands of starting materials.
Multi-week planning per attempt

- Manual review cannot be scaled.

- Operational costs for multi-chemist review means either long turnaround times or high project costs.

- Fewer options and contingencies are considered.

Redwood AI Model Process

Multiple pathways generated. Less than **1 minute** per pathway. ~**95%** model accuracy. Abbreviated manual review.

- The model is proprietary and uses large language models trained on over 1 billion molecules and 4 million reactions.

- Every step of the synthesis is automatically cost- and vendor-evaluated from 60+ global sources.

- Safety and environmental predictions included.

REDWOOD AI PLATFORM ROADMAP

Strategic roadmap expanding Redwood's AI-powered chemistry platform into molecular design, candidate generation, and strategic applications including defense.

Today

- AI-powered platform for predicting and optimizing chemical synthesis across drug discovery, chemical manufacturing, and defense-related applications. Each deployment captures synthesis and reaction data that supports future candidate generation.

Next

- Further integration into molecular design, synthesis optimization, and chemical analysis, supporting broader adoption across pharmaceuticals, industrial chemistry, and defense applications.

Future

- AI-enabled candidate generation and expanded platform capabilities supported by growing synthesis and reaction datasets, including potential proprietary drug candidates and advanced defense applications.

COMPETITIVE LANDSCAPE:
AI CHEMISTRY AND SYNTHESIS INTELLIGENCE

Company	Cost Included?	Synthesis Captured?	Scale Included?	Safety Included?	Environment Review?
Redwood AI, 2026	+	++	+	+	+
IBM RXN	−	+	−	−	−
Iktos Spaya	+	+	−	−	−
Merck Synthia	+	+	−	+/−	+/−
ChemAIRS	−	+	+	+/−	−

Sources: Company websites, product documentation, published literature, and management's assessment as of February 2026.

+ = native capability, +/− = partial or via companion tool,− = not available

COMPARABLE AI PLATFORMS

Company	Market Cap / Capital Raised (USD)	Focus	Notes
Insilico Medicine	$400M+ Raised	Generative Drug Discovery	AI driven generative drug discovery platform. AI designed candidates advanced to clinical trials.
RECURSION	$1.89B Market Cap	AI Drug Discovery	AI for drug discovery platform. Publicly listed with major pharma partnerships.
ANDURIL	$3B+ Raised	Defense AI	AI-driven defense technology company developing autonomous systems and defense platforms. Focus on AI-enabled national security and military applications.
Palantir	$366B Market Cap	AI Platforms / Defense	AI data and analytics platform used by governments, defense agencies, and enterprises. Widely deployed across national security, intelligence, and defense applications.

WHO WE ARE

- Two successful private company exits and multiple IPOs.

- Experience ranging from chemistry and data science to financing.

- Affiliations with top US and Canadian Universities.

- Public company experience, listings on NASDAQ, CSE, TSX and TSX-V.

Team

Louis Dron, MSc – CEO

Kristian Thorlund, PhD – President & Director

Glenn Sammis, PhD – Head of Chemistry

Ofir Harari, PhD – Head of AI

Prince Lat, PhD – Senior Data Scientist

Joey Lai – Research Scientist

Directors & Officers

Nico Mah – CFO & Corporate Secretary

Masoud Darbandi – Director

Graydon Bensler – Director

Zachary Stadnyk – Director

Matthew Mingay – Director

TEAM

Louis Dron, MSc
CEO

Mr. Dron is a healthcare executive with multidisciplinary experience spanning clinical science, health technology, and leadership roles across corporate and research settings. His background includes clinical diagnostics and leading research teams focused on real-world evidence in healthcare. He began his career at the UK National Health Service, later transitioning into senior research and development leadership roles integrating real-world evidence, biostatistics, and epidemiology into healthcare decision-making. Mr. Dron also serves as an advisor to the Canadian Drug Agency and the Bill & Melinda Gates Foundation and is a graduate of the University of Manchester and the University of Leicester.

Kristian Thorlund, PhD
President & Director

Dr. Thorlund, with over 15 years of experience in data science and AI, is an established serial entrepreneur having been involved in the foundation of five Canadian-based businesses, with two successful multi-million dollar exits, over the past decade focused on health technologies. Kristian is an expert in AI and data analysis, ranking within the top 1% of researchers in his field worldwide by citation count. Alongside his business interests, Kristian is a part-time professor at McMaster University, acquiring over $6 million in grants. He has also held an academic appointment at Stanford University and has collaborated extensively with the Bill & Melinda Gates Foundation. He is a graduate of the University of Copenhagen and McMaster University.

Glenn Sammis, PhD
Head of Chemistry

Dr. Sammis is a worldwide leader in chemistry, acting as an accomplished academic with nearly two decades of experience. Currently, a professor at the University of British Columbia, he has built an exceptional teaching record, excelling across a wide range of courses, student evaluations, course development, creation of innovative materials, and teaching leadership. At his time at UBC, Dr. Sammis has acquired over $5.5m in grants. Outside of his research group being at the forefront of pioneering advances in radical and photochemical processes, Glenn has acted as an advisor for synthesis problems for over 10 private companies. He is a graduate of Stanford University and Harvard University.

Ofir Harari, PhD
Head of AI

Dr. Harari is a highly experienced statistician and data scientist with over 15 years of experience across various industries, including healthcare, pharmaceuticals, finance and academia. He has a proven track record in both practical data analysis and methodological research, consistently mentoring teams and advancing innovative solutions in healthcare, AI, and statistical science. In recent years, in addition to his tenure at Redwood AI, he served as a Head of Biostatistics at Purpose Life Science and has previously worked for PayPal. He is a graduate of Ben Gurion University and Tel Aviv University.

Prince Lat, PhD
Senior Data Scientist

Dr. Lat is a passionate researcher and data scientist with a decade of experience. His research spans multiple disciplines, including bioinformatics, biophysics, biochemistry, molecular biology, and DNA nanotechnology. He has also worked in biostatistics and data science, applying these tools to extract insights from complex datasets. He is a graduate of IIT Kanpur and Simon Fraser University.

TEAM CONT'

Nico Mah
CFO & Corporate Secretary

Mr. Mah is a Chartered Professional Accountant and has nearly 8 years of experience in auditing and public accountancy, having been an associate and subsequently a manager at PricewaterhouseCoopers LLP, the global audit and assurance, tax, deals and consulting firm from September 2015 to January 2023. He holds a Bachelor of Commerce degree, majoring in Accounting, from the University of Calgary and a CPA designation in Alberta, Canada.

Zachary Stadnyk
Director

Mr. Stadnyk is a public company executive with over 15 years of experience across healthcare, wellness, technology, cannabis, and private equity. He has held senior capital markets and leadership roles, including Head of Corporate Finance at The Supreme Cannabis Company, founder of DC Acquisition Corp. (TSXV), Head of Life Sciences at the TSX and TSXV working with more than 140 listed issuers, and Chief Executive Officer of Love Pharma Inc. He holds a Bachelor of Commerce in Entrepreneurial Management from Royal Roads University.

Graydon Bensler
Director

Mr. Bensler is a financial professional and Chartered Financial Analyst with experience advising private businesses and publicly traded companies in Canada and the United States. He has held investor relations and capital markets roles, including at Kin Communications Inc. and Evans & Evans, and has served as a director of publicly listed companies including Qualigen Therapeutics Inc., Onco-Innovations Limited, and Health Logic Interactive Inc. Mr. Bensler holds a Bachelor of Management and Organizational Studies with a specialization in Finance from the University of Western Ontario.

Masoud Darbandi
Director

Mr. Darbandi is a sales strategist with over 30 years of experience leading national distribution and client relations across the professional wellness industry. He has driven growth for established brands including WELLA, AMERICAN CREW, and NIOXIN and brings experience in commercialization, customer engagement, and brand development within complex stakeholder environments.

Matthew Mingay
Director

Mr. Mingay is a Research Data Scientist at Lawrence Berkeley National Laboratory (UC Berkeley) working at the intersection of biotechnology, computer science, and artificial intelligence. He has over ten years of experience in molecular biology and data science and has contributed to peer-reviewed research in areas including cancer genomics and epigenetics.

REDWOOD AI HIGHLIGHTS

Expanding Market Opportunity

- Embedded within the $1.65T (2024) global pharmaceutical market, projected to exceed ~$2.35T by 2030[1]
- Operating within the $197.4B+ (2025) global CDMO infrastructure market[2]
- Positioned within the $6.9B (2025) AI-enabled drug discovery market, projected to reach ~$17.81B by 2034[3]
- AI-enabled chemical intelligence applications are increasingly relevant to defense and national security sectors, where global defense spending exceeds $2.7T (2024) annually.[4]

Proprietary AI-Powered Technology

AI-powered chemistry platform designed to model, predict, and optimize chemical synthesis pathways. Internally benchmarked model performance demonstrates strong predictive accuracy across tested datasets, supported by a growing proprietary reaction dataset.

Compounding Data Advantage

Each platform deployment captures structured synthesis and reaction data, expanding Redwood's proprietary dataset. This growing data foundation improves model performance over time and enables deeper chemical intelligence capabilities and future platform expansion.

Broad Applicability Across Scientific Markets

Applicable across pharmaceuticals, biotechnology, industrial chemistry, and strategic sectors including defense, supporting drug development, synthesis planning, intellectual property assessment, and broader chemical intelligence use cases.

Clear Commercialization Strategy

Subscription-based SaaS platform serving pharmaceutical and biotechnology organizations, with strategic expansion toward AI-enabled candidate generation and comprehensive drug pipeline support, including potential proprietary asset development.

Experienced Leadership Team

Led by a multidisciplinary team with expertise in artificial intelligence, data science, chemistry, and healthcare, supported by academic and industry experience.

Source 1: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report
Source 2: https://www.precedenceresearch.com/pharmaceutical-cdmo-market
Source 3: https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market
Source 4: https://www.sphericalinsights.com/press-release/defence-spending-market

CAPITAL STRUCTURE

As of March 11, 2026

Common Shares Issued & Outstanding:	**33,508,750**
Warrants:	**6,774,300**
Issued & Outstanding Fully Diluted:	**42,183,050**

Redwood AI

Contact

Address:

1309-7th Street SW
Calgary, AB, T2R 1A5
Canada

investors@redwoodai.com

www.redwoodai.com